- For Patients
- Introduction to the Marshall Protocol
- Length of the MP
- Immunopathology
- Managing immunopathology
- Food and drink
- Light restriction
- Vitamin D metabolite calculator - get feedback on vitamin D results
- Therapeutic probe - best method for determining MP suitability
- Starting the Marshall Protocol
- Resources for patients
- Marshall Protocol summary
- Palliative vs. curative treatments
- Patient interviews on Bacteriality
- Non-MP treatments
- Glossary
- The Protocol
- Marshall Protocol summary
- Publications and presentations
- Science behind immunopathology
- Science behind olmesartan (Benicar)
- Safety of olmesartan
- Resources for physicians
- Vitamin D metabolite calculator - get feedback on vitamin D results
- Therapeutic probe - best method for determining MP suitability
- Physicians' concerns about the MP
- Notice for emergency medical personnel
- The Pathogenesis
- Publications and presentations
- Science behind Marshall Pathogenesis
- Microbes in the human body
- Successive infection and variability in disease
- Autoimmune theory of disease
- Science behind vitamin D
- Metabolism of vitamin D and the VDR
- Th1 Spectrum Disorder - how chronic inflammatory diseases are related
- Transmission of bacteria and onset of chronic disease
- Evolutionary perspective on disease
- Incidence and prevalence of disease
- Evidence that chronic disease is caused by pathogens
- Diseases
- Foundation
- Related Sites
Differences
This shows you the differences between two versions of the page.
| Both sides previous revisionPrevious revision | |||
| home:mp:olmesartan:response [06.05.2019] – [Patient response to olmesartan (Benicar)] sallieq | home:mp:olmesartan:response [09.14.2022] (current) – external edit 127.0.0.1 | ||
|---|---|---|---|
| Line 33: | Line 33: | ||
| < | < | ||
| - | Olmesartan is classified as an Angiotensin II Receptor Blocking (ARB) drug. When olmesartan binds and blocks the Angiotensin Receptor, it prevents fibrotic tissue from forming and [[http:// | + | Olmesartan is classified as an Angiotensin II Receptor Blocking (ARB) drug. When olmesartan binds and blocks the Angiotensin Receptor, it prevents fibrotic tissue from forming and [[https:// |
| For this reason, [[dosing|higher doses or more frequent administration]] of olmesartan is strongly recommended during [[home: | For this reason, [[dosing|higher doses or more frequent administration]] of olmesartan is strongly recommended during [[home: | ||
| Line 41: | Line 41: | ||
| + | < | ||
| ===== Notes and comments ===== | ===== Notes and comments ===== | ||
| * Legacy content | * Legacy content | ||
| - | * http:// | + | * https:// |
| - | * http:// | + | * https:// |
| - | * http:// | + | * https:// |
| - | * http:// | + | * https:// |
| - | * http:// | + | * https:// |
| ===== References ===== | ===== References ===== | ||
| - | + | </ | |
home/mp/olmesartan/response.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.